Alternatively, relapse-free survival (RFS) was significantly shorter in high versus low CLDN2 or CLDN5 expression in breast cancer [128,129], with high CLDN4 expression also being associated with worse RFS [121]. The gene discussed is CLDN4; the disease is breast carcinoma.